Issuer and category are assigned by StocksXray rules from the fund name. Expense ratio and net assets come from SEC filings; where a fund does not file them (for example grantor trusts) the field stays empty.
Returns and risk
1 month
+10.0%
3 months
+12.4%
6 months
+8.7%
Year to date
−7.8%
1 year
n/a
3 years a year
n/a
5 years a year
n/a
10 years a year
n/a
Volatility (1 year)
21.9%
Largest drop, last year
−24.2%
Largest drop in our data
−24.2%
Total return includes distributions, from end-of-day prices adjusted for splits and distributions, to 22 Oct 2026. Periods of 3 years and longer are annualised and shown only when the fund's history is long enough. Volatility is the standard deviation of daily returns over the last year, annualised. Past performance does not guarantee future results.
Cost: expense ratio
0.98% a year
On $10,000 invested that is about $98 a year in fund costs, taken out of the fund's assets.
Source: the fund's prospectus, as filed with the SEC on 16 Oct 2025 (risk/return summary data). Brokerage commissions and the bid-ask spread are separate costs.
Income: distributions
AKRE paid no distributions in the last 12 months. Its return comes from price change only.
Cash paid per current share (restated for share splits), before tax, from EODHD.
The top 10 make up 80.9% of the fund, out of 19 holdings.
Positions as of 31 Jul 2026, from the fund's Form N-PORT filed with the SEC. Public N-PORT holdings are quarter-end positions published about 60 days later, so they can be months old and the fund may have changed since.
X-Ray look-through
StocksXray scores 66% of AKRE by weight (12 stocks in our S&P 500 coverage), so we can look inside the fund with our own numbers. The weighted average X-Ray Score of those stocks is 56 out of 100.
Weights are the SEC holdings weights dated 31 Jul 2026; scores and fair-value labels are today's. Labels follow our fair-value method ("Undervalued" means fair value is more than 17.5% above the price) and are model estimates, not forecasts or advice. How the X-Ray Score works.
AKRE: frequently asked questions
What is AKRE?
AKRE is the Akre Focus ETF, listed on NYSE. By our rules it is classed as "Equity". Its latest SEC filing lists 19 holdings.
What is the expense ratio of AKRE?
AKRE charges 0.98% a year, according to its prospectus filed with the SEC on 16 Oct 2025. On $10,000 that is about $98 a year in fund costs.
Does AKRE pay dividends?
No. We found no distributions for AKRE in the last 12 months.
What does AKRE hold?
The largest holdings in the latest SEC filing are Mastercard Inc (14.2%), Constellation Software Inc/Can (12.7%), Brookfield Corp (7.3%). The top 10 together make up 80.9% of the fund.
How does StocksXray rate the stocks inside AKRE?
We score 66% of the fund by weight (12 stocks) with our X-Ray Score: the weighted average is 56 out of 100. These are model estimates, not forecasts or advice.
Where the numbers come from
Prices and distributions end-of-day data from EODHD; returns are our own calculations from it.
Expense ratio and holdings SEC filings (prospectus risk/return data and Form N-PORT).
Category, issuer and leverage assigned by StocksXray rules from the fund name.
X-Ray look-through our scores applied to the SEC holdings.
StocksXray is for education only and is not financial advice or a recommendation to buy or sell anything. Past performance does not guarantee future results; funds can lose value.
